Aspirus Regional Cancer Center

Cancer Clinical Trials

This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.

Brain

Trial Name: Name of Trial: Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With Or Without AMG 386 In Patients With Recurrent Glioblastoma Or Gliosarcoma

Protocol ID: RTOG 1122

Eligibility:

Eligibility:

  • Histologically proven diagnosis of glioblastoma or variants (gliosarcoma, glioblastoma with oligodendroglial features, giant cell glioblastoma).  Patients will be eligible if the original histology was a lower grade glioma and a subsequent histological diagnosis of glioblastoma or variants is made 
  • Age 18 years and older
  • Patients must meet required laboratory values
  • Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to study entry
  • Women of childbearing potential and male patients who are sexually active must practice adequate contraception during therapy and for 180 days (6 months) afterwards

Ineligibility:

  • Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years [For example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible)
  • More than 2 relapses
  • Intratumoral hemorrhage or peritumoral hemorrhage
  • Prior therapy with anti-VEGF targeted agents (e.g. bevacizumab, cediranib, vandetanib, aflibercept, sunitinib, sorafenib, etc.).  Prior therapy with thalidomide and lenalidomide is allowed as long as treatment has not occurred within 30 days prior to enrollment
  • Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
  • Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects
  • Known coagulopathy that increases risk of bleeding or a history of clinically significant hemorrhages in the past
  • Prior allergic reaction to the study drugs involved with this study

Acquired immune deficiency syndrome (AIDS) 

Enrollment: 127 Patients

Benefits:

  • Taking part in this study may or may not make your health better.  While researchers hope bevacizumab and AMG 386 is more effective in fighting your brain tumor by slowing its growth, stopping growth, or shrinking the tumor as compared to bevacizumab alone, there is no proof of this yet.  We do know that the information from this study will help researchers learn more about bevacizumab and AMG 386 as a treatment for cancer.  This information could help future cancer patients.

Contact:

Contact:

These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353.

Created: Jul 19, 2013

Updated: Feb 24, 2014

« Return to Trials